마이크로바이옴 시퀀싱 서비스 시장 예측 : 유형, 서비스, 기술, 용도, 최종사용자, 지역별 분석(-2034년)

According to Stratistics MRC, the Global Microbiome Sequencing Services Market is accounted for $2.22 billion in 2026 and is expected to reach $5.85 billion by 2034 growing at a CAGR of 12.9% during the forecast period. Microbiome sequencing services analyze the DNA of microorganisms in a sample to reveal details about the diverse community of microbes living in a particular environment, like the human gut. It is crucial for personalized medicine, disease diagnostics, and advancing our understanding of the intricate interplay between microbiota and various ecosystems. These services identify and quantify microbial species, helping researchers and clinicians understand the microbiome's composition and function.

According to the data updated by Cancer Australia in 2022, it was estimated that 162,163 new cases of cancer would be diagnosed in Australia in 2022, out of which 88,982 would be males and 73,181 females.

Market Dynamics:

Driver:

Expanding biopharmaceutical research

Biopharmaceutical companies are increasingly recognizing the pivotal role of the microbiome in influencing human health and disease, paving the way for the development of targeted therapies and precision medicine approaches. Biopharmaceutical companies leverage microbiome sequencing to conduct preclinical and clinical trials, aiming to understand the impact of therapeutic interventions on microbial ecosystems. Furthermore, the exploration of the gut microbiome, in particular, has garnered attention for its potential in modulating drug metabolism, efficacy, and safety, which is boosting this market size.

Restraint:

High cost

Smaller research institutions, academic laboratories, and startups face unique financial challenges that prevent their capacity to conduct thorough microbiome sequencing services due to high costs. Financial obstacles for researchers and organizations are made worse by these high costs, which include sample collection, DNA extraction, library preparation, and data analysis. Additionally, the complexity of microbiome analysis, which necessitates sophisticated sequencing technologies and bioinformatics knowledge, adds to the overall high cost of these services, which is hindering this market size.

Opportunity:

Innovations in sequencing technologies

The technological strides enable researchers to generate vast amounts of data, facilitating a more comprehensive understanding of microbial communities within diverse ecosystems. Technologies such as next-generation sequencing (NGS) platforms, Illumina's, and Thermo Fisher's offerings have significantly enhanced the depth and breadth of microbiome sequencing. Furthermore, improved sequencing accuracy, longer read lengths, and increased throughput contribute to the identification and characterization of a wider range of microbial species, thereby propelling this market expansion.

Threat:

Risks associated with standardization

The lack of uniformity in protocols, methodologies, and data analysis procedures across different platforms and service providers introduces challenges in comparing and interpreting results. This variability can lead to inconsistencies in microbial community profiling. Furthermore, the absence of standardized practices in sample collection, DNA extraction, and sequencing library preparation can contribute to biases and errors in microbiome data. This not only affects academic research but also impacts the translation of microbiome sequencing into clinical applications and regulatory frameworks, hindering the market's growth.

Covid-19 Impact

The COVID-19 pandemic has negatively impacted the microbiome sequencing services market in various ways. Disruptions in supply chains, logistical challenges, and restrictions on laboratory activities have impeded the seamless operation of microbiome sequencing services. Many research institutions and biotechnology companies faced financial constraints, further limiting investments in microbiome studies and sequencing services. Additionally, clinical trials and academic research activities decreased demand for microbiome sequencing services in both academic and industrial settings, impeding this market's growth.

The whole-genome sequencing segment is expected to be the largest during the forecast period

The whole-genome sequencing segment is estimated to hold the largest share during the forecast period, due to its ability to capture a broad spectrum of genetic information, enabling the detection of rare species and variations within microbial communities. Additionally, this technique involves sequencing the entire DNA of an organism, providing a detailed understanding of its genetic makeup, functional elements, and potential virulence factors. It is instrumental in fueling discoveries and guiding therapeutic interventions, thereby driving this segment's growth.

The sequencing by ligation (SBL) segment is expected to have the highest CAGR during the forecast period

The sequencing by ligation (SBL) segment is anticipated to have highest CAGR during the forecast period. In SBL, DNA fragments are ligated together using specific adapters, forming a concatemeric structure. This offers advantages such as high accuracy, long read lengths, and the ability to capture information from challenging genomic regions. In addition, researchers and service providers obtain comprehensive insights into microbial genomes, aiding in the understanding of community dynamics, functional potential, and host-microbiome interactions, which are boosting this market expansion.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period owing to increasing awareness of the microbiome's impact on health and disease, coupled with a rising emphasis on precision medicine and personalized healthcare. Countries like China, Japan, South Korea, and India foster collaborations between research institutions, biotechnology companies, and sequencing service providers. In addition, as research capabilities and infrastructure continue to strengthen the advancements in high-throughput sequencing technologies and bioinformatics capabilities further propel the region's growth.

Region with highest CAGR:

Europe is expected to witness highest CAGR over the projection period. The diverse population across Europe provides a rich landscape for microbiome studies, enabling researchers to explore variations in microbial compositions and their impact on regional health patterns. Key players such as Illumina, Inc., Macrogen, Inc., Genewiz, and Eurofins Scientific also contribute significantly to advancements in personalized medicine, agricultural practices, and our understanding of microbial ecosystems, thus driving this region's expansion.

Key players in the market

Some of the key players in the Microbiome Sequencing Services Market include DNA Genotek Inc., Thermo Fisher Scientific Inc., Illumina, Inc., Metabiomics, CosmosID, Zymo Research, Corporation, PerkinElmer, Inc., BGI Genomics Co., Ltd., Rancho Biosciences, Baseclear BV, Diversigen, Inc., Merieux Nutrisciences Corporations, Clinical Microbiomics AS, Bio-Rad Laboratories, Inc. and Genewiz Inc.

Key Developments:

In November 2023, Illumina Inc., a global leader in DNA sequencing and array-based technologies announced the launch of the Global Health Access Initiative to support access to pathogen sequencing tools for public health in low- and middle-income countries (LMICs).

In October 2023, Thermo Fisher Scientific, the world leader in serving science, has introduced the Thermo Scientific(TM) Meridian(TM) EX System- an electron-beam-based failure analysis solution designed to enable precise fault localization on advanced semiconductor logic technologies.

In July 2023, Bio-Rad Laboratories, Inc. announced that the companies have agreed to settle their patent dispute pending in the U.S. District Court of Delaware pursuant to a global settlement and patent cross-licensing agreement relating to digital PCR technology.

Types Covered:

• Shotgun Sequencing
• Whole-genome Sequencing
• Amplicon Sequencing
• Other Types

Services Covered:

• Data Analysis
• Sample Preparation
• Sequencing Library Preparation
• Other Services

Technologies Covered:

• Targeted Gene Sequencing
• Sequencing by Ligation (SBL)
• Sequencing by Synthesis (SBS)
• Other Technologies

Applications Covered:

• CNS Diseases
• Oncology
• Gastrointestinal Diseases
• Infectious Diseases
• Other Applications

End Users Covered:

• Academic and Research Institutes
• Pharmaceutical and Biotechnology Companies
• Other End Users

Regions Covered:

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • New Zealand
  • South Korea
  • Rest of Asia Pacific
• South America
  • Argentina
  • Brazil
  • Chile
  • Rest of South America
• Middle East & Africa
  • Saudi Arabia
  • UAE
  • Qatar
  • South Africa
  • Rest of Middle East & Africa

What our report offers:

• Market share assessments for the regional and country-level segments
• Strategic recommendations for the new entrants
• Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
• Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
• Strategic recommendations in key business segments based on the market estimations
• Competitive landscaping mapping the key common trends
• Company profiling with detailed strategies, financials, and recent developments
• Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

• Company Profiling
  • Comprehensive profiling of additional market players (up to 3)
  • SWOT Analysis of key players (up to 3)
• Regional Segmentation
  • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
  • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

• 2.1 Abstract
• 2.2 Stake Holders
• 2.3 Research Scope
• 2.4 Research Methodology
  • 2.4.1 Data Mining
  • 2.4.2 Data Analysis
  • 2.4.3 Data Validation
  • 2.4.4 Research Approach
• 2.5 Research Sources
  • 2.5.1 Primary Research Sources
  • 2.5.2 Secondary Research Sources
  • 2.5.3 Assumptions

3 Market Trend Analysis

• 3.1 Introduction
• 3.2 Drivers
• 3.3 Restraints
• 3.4 Opportunities
• 3.5 Threats
• 3.6 Technology Analysis
• 3.7 Application Analysis
• 3.8 End User Analysis
• 3.9 Emerging Markets
• 3.10 Impact of Covid-19

4 Porters Five Force Analysis

• 4.1 Bargaining power of suppliers
• 4.2 Bargaining power of buyers
• 4.3 Threat of substitutes
• 4.4 Threat of new entrants
• 4.5 Competitive rivalry

5 Global Microbiome Sequencing Services Market, By Type

• 5.1 Introduction
• 5.2 Shotgun Sequencing
• 5.3 Whole-genome Sequencing
• 5.4 Amplicon Sequencing
• 5.5 Other Types

6 Global Microbiome Sequencing Services Market, By Service

• 6.1 Introduction
• 6.2 Data Analysis
• 6.3 Sample Preparation
• 6.4 Sequencing Library Preparation
• 6.5 Other Services

7 Global Microbiome Sequencing Services Market, By Technology

• 7.1 Introduction
• 7.2 Targeted Gene Sequencing
• 7.3 Sequencing by Ligation (SBL)
• 7.4 Sequencing by Synthesis (SBS)
• 7.5 Other Technologies

8 Global Microbiome Sequencing Services Market, By Application

• 8.1 Introduction
• 8.2 CNS Diseases
• 8.3 Oncology
• 8.4 Gastrointestinal Diseases
• 8.5 Infectious Diseases
• 8.6 Other Applications

9 Global Microbiome Sequencing Services Market, By End User

• 9.1 Introduction
• 9.2 Academic and Research Institutes
• 9.3 Pharmaceutical and Biotechnology Companies
• 9.4 Other End Users

10 Global Microbiome Sequencing Services Market, By Geography

• 10.1 Introduction
• 10.2 North America
  • 10.2.1 US
  • 10.2.2 Canada
  • 10.2.3 Mexico
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 Italy
  • 10.3.4 France
  • 10.3.5 Spain
  • 10.3.6 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 New Zealand
  • 10.4.6 South Korea
  • 10.4.7 Rest of Asia Pacific
• 10.5 South America
  • 10.5.1 Argentina
  • 10.5.2 Brazil
  • 10.5.3 Chile
  • 10.5.4 Rest of South America
• 10.6 Middle East & Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 UAE
  • 10.6.3 Qatar
  • 10.6.4 South Africa
  • 10.6.5 Rest of Middle East & Africa

11 Key Developments

• 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
• 11.2 Acquisitions & Mergers
• 11.3 New Product Launch
• 11.4 Expansions
• 11.5 Other Key Strategies

12 Company Profiling

• 12.1 DNA Genotek Inc.
• 12.2 Thermo Fisher Scientific Inc.
• 12.3 Illumina, Inc.
• 12.4 Metabiomics
• 12.5 CosmosID
• 12.6 Zymo Research Corporation
• 12.7 PerkinElmer, Inc.
• 12.8 BGI Genomics Co., Ltd.
• 12.9 Rancho Biosciences
• 12.10 Baseclear BV
• 12.11 Diversigen, Inc.
• 12.12 Merieux Nutrisciences Corporations
• 12.13 Clinical Microbiomics AS
• 12.14 Bio-Rad Laboratories, Inc.
• 12.15 Genewiz Inc.